Business Description
Aspire Biopharma Holdings Inc
NAICS : 541713
SIC : 2834
ISIN : US7389201077
Description
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.91 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.78 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -4.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -173 | |||||
3-Year EPS without NRI Growth Rate | -214 | |||||
3-Year FCF Growth Rate | 9.4 | |||||
3-Year Book Growth Rate | -151.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.9 | |||||
9-Day RSI | 63.75 | |||||
14-Day RSI | 57.83 | |||||
3-1 Month Momentum % | 6.34 | |||||
6-1 Month Momentum % | -88.44 | |||||
12-1 Month Momentum % | -98.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.26 | |||||
Quick Ratio | 2.14 | |||||
Cash Ratio | 1.86 | |||||
Days Inventory | 2859.17 | |||||
Days Payable | 14905.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.9 | |||||
Shareholder Yield % | -38.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 17.65 | |||||
Operating Margin % | -16000 | |||||
Net Margin % | -34594.12 | |||||
EBITDA Margin % | -5661.77 | |||||
FCF Margin % | -18267.65 | |||||
OCF Margin % | -18267.65 | |||||
ROA % | -426.56 | |||||
ROIC % | -79.69 | |||||
3-Year ROIIC % | -361.51 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 26.7 | |||||
PB Ratio | 0.3 | |||||
Price-to-Tangible-Book | 0.3 | |||||
EV-to-EBIT | -2.43 | |||||
EV-to-EBITDA | -2.43 | |||||
EV-to-Revenue | 137.35 | |||||
EV-to-FCF | -0.75 | |||||
| Price-to-Net-Current-Asset-Value | 0.3 | |||||
| Price-to-Net-Cash | 0.45 | |||||
Earnings Yield (Greenblatt) % | -41.15 | |||||
FCF Yield % | -68.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ASBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aspire Biopharma Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.034 | ||
| EPS (TTM) ($) | -156.541 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 185.78 | ||
| 14-Day RSI | 57.83 | ||
| 14-Day ATR ($) | 0.749755 | ||
| 20-Day SMA ($) | 6.2905 | ||
| 12-1 Month Momentum % | -98.95 | ||
| 52-Week Range ($) | 3.309 - 1050.360042 | ||
| Shares Outstanding (Mil) | 1.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aspire Biopharma Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aspire Biopharma Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 109 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 17 days | ||
| General meeting for 2025 | 2026-08-10 | In 14 days | ||
| Life Sciences Investor Forum | 2026-06-25 14:00 | 6.54 (+4.81%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 5.87 (+13.76%) | ||
| 0.0333333:1 Stock Split | 2026-05-11 | 5.55 (+52.39%) | ||
| Annual report for 2025 | 2026-03-30 | 27.40 (+1.26%) | ||
| 0.025:1 Stock Split | 2026-01-16 | 62.28 (-6.65%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 126.24 (+11.91%) | ||
| Sidoti Virtual Investor Conference | 2025-08-20 13:45 | 560.04 (-15.76%) |
Show
Entries
Aspire Biopharma Holdings Inc Frequently Asked Questions
What is Aspire Biopharma Holdings Inc(ASBP)'s stock price today?
The current price of ASBP is $6.97. The 52 week high of ASBP is $1050.36 and 52 week low is $3.31.
When is next earnings date of Aspire Biopharma Holdings Inc(ASBP)?
The next earnings date of Aspire Biopharma Holdings Inc(ASBP) is 2026-08-13 Est..
Does Aspire Biopharma Holdings Inc(ASBP) pay dividends? If so, how much?
Aspire Biopharma Holdings Inc(ASBP) does not pay dividend.
Guru Commentaries on NAS:ASBP
No articles.
Press Release
Articles on Aspire Biopharma Holdings Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers